Clinical Trial Detail

NCT ID NCT02640833
Title A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

CLL/SLL

Therapies

Duvelisib + Venetoclax

Age Groups: adult

No variant requirements are available.